Subscribe
The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.
Weekly Roundup: June 15-19
Weekly Roundup: June 8-12
EMA accepts marketing application for tralokinumab
Patient enrollment complete for tapinarof long-term safety study for psoriasis
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD